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1. Introduction 
In addition to advancing our understanding of RCC, improved abdominal imaging 
technology has caused a migration of tumor stage and alteration of surgical strategies, with 
tumors commonly being diagnosed at an earlier stage. Despite these advances, the 
prognosis for patients with metastatic RCC is poor. Of the total number of patients with 
renal cancer, approximately a third either presents with or later develops metastatic disease. 
Unfortunately, for these patients, contemporary systemic therapies are generally 
ineffective—median survival is less than 1 year. Despite adjuvant systemic chemotherapy, 
hormonal or cytokine therapies, used alone or in combination, overall response rates rarely 
exceed 20% and durable, complete responses are rare. Targeted therapy in the management 
of metastatic renal cell cancer is newly introduced to urology practise. These drugs were 
used in very limited number of patients and only for clear cell histology. No 
recommendation to use these drugs for other than clear cell histology was seen in the 
literature. Nevertheless, there is a encouraging responses in trials with limited number of 
patients in the literature. Future advances are expected. 
Spontaneous remissions in 0.8–7.0% of patients are reported in surgical series of clinical 
trials with previous surgical intervention. The role of surgical intervention in patients with 
metastatic renal cancer can be twofold. First, to render a patient clinically free of all sites of 
metastases ('metastasectomy'). Second, to resect the primary tumor prior to initiation of 
systemic therapy ('cytoreductive nephrectomy').  
Studies that examine combinations of surgery and systemic therapy aim to improve survival 
in this high-risk group. In an attempt to address this important clinical issue, two 
randomized, prospective clinical trials were organized in the US (Southwest Oncology 
Group [SWOG]) and Europe (European Organization for Research and Treatment of Cancer 
[EORTC]) under similar entry criteria. The trials compared treatment of metastatic renal 
cancer with cytoreductive nephrectomy plus IFN-2b versus IFN-2b alone. Median 
survival of patients that underwent cytoreductive nephrectomy plus IFN-2b was 
significantly greater than that of those treated with IFN-2b only.  
More recent metastasectomy studies also identified favorable clinical and surgical 
characteristics that were associated with a positive enhancement of outcome, but 
metastasectomy has never been assessed in a randomized clinical trial. It is not certain that 
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metastasectomy can be curative, but operative intervention can provide effective palliation 
for symptomatic metastases in sites such as bone, the brain, and the adrenal gland. 
Ultimately a prospective clinical trial comparing metastasectomy to best standard systemic 
therapy will define the exact role of this approach.The occasionally unpredictable natural 
history of renal cancer and varying patient selection criteria can make the interpretation of 
outcomes from different centers difficult. As a conclusion although there is a tendency in 
favor of surgery, operative intervention for metastatic renal cancer is still controversial.    
The aim of this review is more recent management modalities in the management of 
metastatic renal cell carcinoma. In addition, the role of surgery in metastatic RCC have been 
emphasised.    
2. The role of nephrectomy 
Although it is a part of multidisciplinary approach in the management of metastatic renal 
cell carcinoma (RCC), the role of Cytoreducive nephrectomy is still controversial in urologic 
literature. Recently according to some multicentric prospective randomized trials, because 
of providence little survival advantage, cytoreductive nephrectomy has gained some 
popularity. The objectives of nephrectomy in metastatic disease are avoidance of local 
symptoms and negative effects of primary tumor on immunological system (asynergy) and 
obtaining suitable nominee for immunotherapy, increasing patient quality of life and 
probably increased response to systemic therapy and finally increased overall survival. On 
the other hand, to prevent new metastases from primary tumor, capture of circulating 
immune cells, especially lymphocytes, which absorbed from primary tumor and so 
properties of immune pressure of primary tumor on immune system. Decreasing tumor 
burden may help the effectiveness of systemic therapy on tumor.  
Surgical mortality rates are reported as 2-11%. In NCI trial, 62% patients can take 
immunotherapy and response rate is 18% in 195 patients. In this trial 38% patients cannot 
take immunotherapy because of complications of nephrectomy or rapid deterioration in 
general performance after progression of the disease (6). Some oncological centers 
recommend primary immunotherapy in order to avoid surgical morbidity especially in 
patients with clinical regression in metastatic sites (7,8). 
Actually, two points provide that nephrectomy is a safe procedure; one is observation of 
spontaneous regression phenomena in metastatic sites after nephrectomy which is very 
rare. Freed has reported that 51 patients presented spontaneous regression after 
nephrectomy in literature (9). Similarly, NCI reported 4 patients (4.4%) have 
demonstrated spontaneous regression in 99 patients (10). In these 4 patients have only 
lung metastases and they were in remission for mean 24.3 months. Although spontaneous 
remission rates are very low, it is still very objective data in favor of nephrectomy. The 
other point for nephrectomy is unresponsiveness of primary tumor to systemic therapy. 
Radical nephrectomy may help to increase objective responses to systemic therapy. It has 
been obtained 32% objective response with immunotherapy after nephrectomy in 55 
patients, but 4.7% response rate has been observed with same immunotherapeutic 
regimen in insitu tumor (11). Recently, surgical technique for cytoreductive nephrectomy 
is getting importance. Minimal invasive techniques gain popularity. While laparoscopic 
experience increased, laparoscopic radical nephrectomy performance is increasing in 
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literature. The surgery time is longer, but postoperative analgesic requirements and 
hospital stay are decreasing. Therefore patients can take systemic therapy earlier than 
open surgery (Mean 35 vs 67 day). Patients without immunotherapy in case of disease 
progression are 13-77 % in literature (16). The shared conclusion of all the reports in 
literature is that the patients for cytoreductive nephrectomy have to be selected and they 
have to be in good ECOG performance status.  
The last clues for nephrectomy are quality of life. Hematuri, pain and paraneoplastic 
syndromes including anemia, anorexia, hypertension, hypocalcaemia etc. can be controlled 
with nephrectomy.  
In conclusion, multidisciplinary approach including surgery stands in the forefront. But 
some questions are on the agenda. Timing and coordination. Which one should be the first, 
nephrectomy or systemic therapy? 
 
O: Observation 
N: Nephrectomy 
Fig. 1. SWOG and EORTC trials 
3. Metastasectomy 
For a long time, if possible excision of metastases is recommended. Complete 
metastasectomy was performed in Kierney” report. 59% and 31% 3 and 5 years survival was 
obtained in 77 patients with metastatic RCC. These survivals were significantly different 
from patients within conservative follow (20,21). In another retrospective study with 278 
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patients, complete and incomplete metastasis resection can provide 44% vs 14% 5-years 
survival advantage (22).  
In conclusion, the presence of solitary metastases and localization are important factors for 
clinical improvement. Resection of solitary metastases is recommended for survival and also 
quality of life.  
4. Systemic treatments 
4.1 Cytotoxic drugs 
Standard cytotoxic drugs are generally ineffective. Response rates were reported below 10%.  
Response rate was reported 17% with Gemcitabine and 5-Florourasil combination in phase 
II study. Gemcitabine and  capecitabine combination is effective as 20%. But grade 3-4 
toxicity was reported. Same regimen reported by CALGB, Survival was 12% and stable 
disease rate was 59% in this study. Nevertheless toxicity was always a problem. 36% of 
patients could not continue the treatment protocol. The main problem is neutropenie and 
hand-food syndrome. Therefore, phase III studies can not be conducted.       
4.2 Immunotherapy  
Standard theurepathic regimen is still lack in the management of metastatic RCC. But 
interferon and interleukin therapy is in management list in many centers. Histological 
type is the most important factor for the response. The only histological type which is 
sensitive to immunotherapy is clear cell RCC. Granular, papillary or sarcomatoid type 
variants are resistant to immunotherapy. The main mechanism of cytokines is still 
contraversial. Cytokines are binding to specific receptors on tumor cells and initiate 
intracellular and intercellular signal mechanism. IL-2 is a potent stimulator of T cell 
proliferation. Anti-tumor T cells rapidly begin to proliferation, then tumor-specific 
cytotoxic T lymphocytes=CTL, natural killer lymphocytes=NK and probably intratumoral 
lymphocytes=TIL become active and try to kill tumor cell. However, interferons have 
some antiangiogenetic effects. Absence of anemia and hypocalcaemia, normal lactic 
dehydrogenase, prior nephrectomy and good performance status increase possibility of 
positive response.  
The main expectations for immunotherapy in metastatic RCC 
 Overhelming of T-lymphocite dysfunction, dendrtic cell dysfunction, soluble inhibitory 
factors secreted from tumor cells (IL-10), 
 The changes of T-lymphocite antigen receptors and transmission of signals (TCRdelta, 
decreasing p56 levels, NFkappaB compliment changes) 
 Identification of unique tumor surface antigens 
 Vaccination manuplations for immun tolerence 
Current immunotheraupeutic cytokines are; 
 Interferons 
 İnterleukins 
 Colony-stimulating  factors (CSF) 
 Tumor necrosis factor (TNF) 
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4.3 Interferon 
IFN-alpha is approved for the management of metastatic RCC in Europe and it is used 
routinely in Urological practise. Response rates are 10-25%. Recently, with recombinant 
forms response rates are increased to 29%. Survival advantage is 3-5 months. Toxicities are 
flu-like syndromes, dryness in skin and mucosal membranes, mental changes and 
depression. Combination with IL-2 is frequently applied in many centers. Dosage scheme is 
controversial. 
IFN-beta and gamma are ineffective.  
4.4 Interleukin-2 (IL-2) 
A group of cytocine which are activated and regulated lymphocite growing and/ or 
differantiation  
First described one is IL-2.  
It is produced by activated CD4+ lymphocites.Cytotoxic T cells are stimulated by IL-2. 
CD8+ T cells, monocytes, lymphocyte activated killer lymphocytes (LAK) are activated and 
tumor necrosis factor is secreted. It is reported that IL-2 is as effective as 15% in many series. 
Rekombinant IL-2 (rIL-2) 
 Bolus high-dose i.v. infusion= highly toxic 
 İnhalation  
 Response rate 7-27% 
 Only clear cell type is respondable 
Recently, there are more than 10 interleukin described other than IL-2 (IL-4; IL-7; IL-12 have 
been still investigating) 
4.5 Cytokine combination therapy 
Class I MHC Ag expression  + T-lymphocite activation  
 Synergy 
 Mean 22% response 
 Similar response rate as seen in high-dose IL-2    
Phase 1 and 2 studies showed that response rates were 6-30%. Retrospective series showed 
that 15% and 20% response rates, but these results are not statistically significant. 
Nevertheless, mean survival is a little bit meaningful (9.1 vs 13 mos).  
4.6 Targeted therapies 
Since more new agents have been produced and limited number of prospective, 
randomized, placebo-controlled studies have been reported,  Therefore, we have evaluated 
only;   
1. Sorafenib (Nexavar®) 
2. Sunitinib (Sutent®) 
3. Bevasizumab (Avastin®) + IFN-alfa 
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4. Temsirolimus (Torisel®) in this review 
Sorafenib and/or sunitinib, a multikinase inhibitor of tumor-cell prolferation and 
angiogenesis, have been shown some activity, in two double blind, placebo-controlled trial 
in patients with metastatic renal cell ca. All the patients’ histology were clear cell ca (24,25). 
Renal cell carcinoma is most aggressive and mortal genitourinary cancer with more than 
40% of patients dying of cancer (26). Unfortunately, no reliable treatment alternative has 
been still conducted for especially metastatic RCC. Recently, investigations in targeted 
therapy including multikinase inhibition and antiangioenesis encouraged the clinicans that 
they have some activity in the management of metastatic RCC. Survival benefit with the 
targeted therapy was demonstrated in two double blind, placebo-controlled study in the 
treatment of metastatic disease (24,25). Nevertheless, there are still many unresponded 
questions. Response rate in different histological type is not clear. We  have administered 
sorafenib in a patient with metastatic RCC with sarcomatoid differentiation and obtained 
excellent result.    
This case report might be an evidence that antiangiogenic agents can be used in any 
histologic type of renal cell carcinoma.  
Additional data on the durability of the response may further clarify the complete response 
and survival benefit 
                                                     Inactive VHL gene 
                                                                 ↓ 
                                                          HIF-1-alfa↑ 
                                                                 ↓ 
                                             HIF-alpha/HIF-beta complex ↑ 
                                                                 ↓ 
                                          Hypoxia induced gene transcription 
                                        ↓               ↓                   ↓                    ↓ 
                                 VGEF↑   PDGF-beta↑   TGF-alpha↑    Erythropoietin ↑ 
Fig. 2. Loss of VHL gene and pathways 
Small molecule inhibitors have mainly targeted growth factor signals, cell cycle regulatory 
factors and angiogenesis. Growth factors like VGEF and PDGF have been effective by 
transmembrane tyrzin kinase receptors which expressed in endothelial cells. They have 
triggered autophosphorilazition of intracellular tyrozin kinase receptors and protein 
activation link with the attachment of extracellular parts of receptors. Recently many small 
molecule inhibitors have been discovered (27,28,29). Raf kinase inhibitors like sorafenib and 
sunitinib, multiple kinase like VEGFR-2, VEGFR-3 and PDGFR inhibitors or mTOR 
inhibitors like temsirolimus, everolimus and epidermal growth factor receptor tyrosine 
kinase inhibitors like erlotinib and lapatinib are the most popular molecules nowadays 
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(30,31). Nevertheless, still prospective, placebo-controlled studies are significantly lacking in 
describing the most effective treatment modality in the management of metastatic RCC (32). 
5. Conclusion 
Cytotoxic chemotherapy and immunotherapy are less effective treatment modalities in the 
management of metastatic RCC. However, better understanding of promotion of RCC 
caused newly produced many targeted therapies. Now, it is early to say that newly 
introduced drugs can solve the problem, but they are encouraging. .Due to SWOG and 
EORTC studies which are the most reliable studies in the literature, still primary 
nephrectomy and combination immunotherapy modalities are the only acceptable choice in 
patients with good performance status for the treatment of metastatic RCC. 
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